Market Access and the Inflation Reduction Act

The Inflation Reduction Act of 2022 (IRA) institutes Medicare changes that include the ability to negotiate drug prices, limit price increases and cap out-of-pocket costs for beneficiaries. Understanding the far-reaching implications of these provisions is crucial for market access professionals to successfully navigate the new dynamics and plan for success in the future.

In this new article, our team of integrated experts outline the provisions and their implications, point out key questions to which market access professionals should have ready answers and offer a spectrum of assistance in finding those answers. Some of the topics included are:

1. Negotiating Drug Price
   • Implications: Price negotiations will impact reimbursement rates, market access, and overall revenue. We must anticipate potential price adjustments and adapt our pricing strategies accordingly.
2. Limiting Price Increases
   • Implications: Our forecasting models need recalibration. How will these limits affect revenue projections? What adjustments should we make to launch pricing and long-term strategies?
3. Out-of-Pocket Cost Caps
   • Implications: While this benefits patients, it affects payer dynamics. How will payers respond? What impact will this have on formulary placement and patient access?
4. Key Questions for Market Access Professionals
5. Assistance Spectrum

In this dynamic landscape, market access strategy is more critical than ever. EVERSANA’s integrated team of experts across agency market access, market and patient access, specialty consulting, NAVLIN consulting, research and learning and performance disciplines understand how to address these questions and provide innovative solutions to help navigate the IRA’s impact and drive successful commercialization. Download the full article to learn more.